Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
INDIANAPOLIS, Nov. 13 /PRNewswire-FirstCall/ -- Eli Lilly and
Company (NYSE:LLY) announced today that Steven M. Paul,
M.D., executive vice president, science and technology, and
president, Lilly Research Laboratories, will retire from Lilly
effective February 28, 2010. Lilly has also announced that Jan M.
Lundberg, Ph.D., executive vice president and head of global
discovery research, AstraZeneca, is to become his successor. Paul
is committed to working closely with Lundberg to ensure a
successful transition. Lundberg plans to join Lilly in Indianapolis
as early as January 2010, subject to completion of the U.S.
Paul joined Lilly as vice president, central nervous system
discovery research and decision-phase medical research, in 1993. He
was named group vice president, therapeutic area discovery research
and clinical investigation, in 1998. Paul has been in his current
role since 2003. Before coming to Lilly, Paul was the scientific
director of the National Institute of Mental Health.
"Under Steve's leadership, we now have the most robust pipeline
in Lilly's history, including approximately 60 unique potential
medicines--both small molecules and biologics--in human testing.
Additionally, Steve has helped to recruit many of the top leaders
we have in LRL today. Steve has also been actively involved in
advancing Lilly's research in the area of Alzheimer's disease,
including solanezumab, one of Lilly's two late-stage Alzheimer's
molecules," said John Lechleiter, Ph.D., Lilly chairman and chief
"Steve has also been instrumental in successfully transforming
R&D over the past several years, including the implementation
of the FIPNet model, moving Lilly from a fully integrated
pharmaceutical company, where we previously owned all aspects of
the value chain, to a fully integrated pharmaceutical network,
where we are playing bigger than our size. He has also been a
tremendous ambassador for the company, representing Lilly through
his involvement with biopharmaceutical industry, scientific, and
medical organizations," added Lechleiter.
Paul had planned to retire in 2010. With the successful
recruitment of his successor, he will retire at the end of February
"Advancing our pipeline to patients as quickly and as safely as
possible is the biggest challenge Lilly faces in 2010 and beyond.
We are confident that Dr. Lundberg will be able to deliver on this
challenge," said Lechleiter.
Lundberg has a Ph.D. from Sweden's world-renowned Karolinska
Institute, where he was a professor in the department of
pharmacology before moving to industry. Prior to Karolinska, he
attended Gustavus Adolphus College in Minnesota and the University
of Gothenburg in Sweden. He has published approximately 500
scientific articles, mainly related to mechanisms of cell signaling
in the nervous, cardiovascular, endocrine and respiratory systems.
Lundberg has won a variety of research awards and is a highly cited
author in the areas of biology and biochemistry, pharmacology and
neuroscience. He has been a member of the Swedish Medical Research
Council and also of the Advisory Board for Drug Approvals at the
Swedish Medical Product Agency. In January 2003, he was appointed
Honorary Doctor of Pharmacy at Uppsala University.
During the last 10 years at AstraZeneca, as head of global
discovery research, Lundberg was instrumental in delivering more
than 150 drug candidates to the company's pipeline. He had
responsibility for discovery research and supported clinical
development of potential therapies for cancer, infection, central
nervous system disorders, pain, cardiovascular, metabolic and
respiratory diseases, gastrointestinal conditions, and
inflammation. Lundberg was also responsible for discovery-enabling
technologies, discovery informatics, drug metabolism and
pharmacokinetics, translational science and safety assessment. He
has had a leading role in external activities, including
in-licensing of projects and technologies, as well as acquisitions
of biotech companies. His organization was involved with both small
molecules and biologics. For the past seven years, he has been an
executive vice president and member of the senior executive team,
reporting to the CEO of AstraZeneca.
"I have always had tremendous respect for the quality of people,
science and products at Lilly. Therefore, I feel honored to be the
successor to Steve Paul. I'm really looking forward to meeting my
colleagues at Lilly and together with them conquering the future
challenges and advancing innovative medicines that meet the needs
of patients, payers and prescribers," said Lundberg.
According to Paul, "Jan possesses the right mix of scientific
expertise and industry experience needed to advance the innovative
pipeline of this company."
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
Posted: November 2009